Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 3.8M | 168.4% |
| Gross Profit | 3.7M | 174.3% |
| Cost of Revenue | 38,000 | 13.6% |
| Operating expense | 7.7M | 4.7% |
| Net Income | -3M | 47.3% |
| EBITDA | -3.7M | 35.4% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 97M | 6% |
| Total Liabilities | 32M | 11.5% |
| Total Equity | 66M | 3.1% |
| Shares Outstanding | 189M | 0% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -5.8M | 11.8% |
| Cash from investing | 3.9M | 144.2% |
| Cash from financing | -3,000 | 102.9% |
EPS
Financial Highlights for Lineage Cell Therapeutics in Q3 '24
Lineage Cell Therapeutics reported a revenue of 3.8M, which is a 168.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 3.7M, marking a 174.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 38,000, a -13.6% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 7.7M, showing a 4.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -3M, showing a 47.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -3.7M, showing a 35.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Lineage Cell Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
